Researchers at the IBS Center for Synaptic Brain Dysfunctions have identified a therapeutic strategy for autism spectrum disorder (ASD) by suppressing the glycine transporter Slc6a20a. By targeting this specific protein, the team successfully restored NMDA receptor (NMDAR) function in mouse models and human cortical organoids, potentially addressing a core mechanism of neurodevelopmental disorders including schizophrenia and intellectual disability.
How does targeting Slc6a20a improve brain function?
NMDARs require both glutamate and glycine to function, acting as essential components for memory, learning, and social interaction. According to Director Kim Eunjoon, previous efforts to boost glycine levels often targeted GlyT1, a transporter found throughout the brain, which led to significant side effects due to its role in breathing and motor control. By contrast, Slc6a20a is expressed primarily in cognition-related regions like the hippocampus and cortex. Suppressing this transporter allows glycine to accumulate where it is needed most, effectively normalizing NMDAR activity without triggering the respiratory or motor complications associated with broader, systemic treatments.
Unlike traditional gene re-expression therapies that aim to replace missing proteins, this approach uses antisense oligonucleotides (ASOs) to modulate existing signaling pathways, which scientists view as a more practical clinical route.
What were the results in autism models?
The research team applied ASO treatment to mouse models carrying SHANK2 and SHANK3 mutations—genetic markers strongly linked to ASD and Phelan-McDermid syndrome. According to the study, the treatment restored NMDAR function and improved behavioral traits, including social interaction and repetitive behaviors. Notably, these improvements occurred in adult mice, a finding that challenges the assumption that neurodevelopmental disorders can only be treated during early “critical periods” of brain development. Further analysis showed that the therapy did not change total protein levels but instead corrected abnormal phosphorylation patterns, suggesting the treatment fine-tunes how existing synapses communicate.
Can these findings translate to human patients?
To evaluate potential human application, the researchers developed cortical organoids using CRISPR gene-editing to replicate SHANK2 and SHANK3 mutations. These organoids exhibited the same NMDAR hypofunction observed in the mouse models. When treated with an ASO targeting the human SLC6A20 gene, the organoid receptor function returned to near-normal levels. According to Director Kim, the consistency between the animal models and human organoid data indicates that this mechanism could serve as a viable framework for treating a spectrum of neuropsychiatric conditions characterized by NMDAR deficiency.
Comparison: Traditional GlyT1 Inhibition vs. Slc6a20a Targeting
| Feature | GlyT1 Inhibition | Slc6a20a Targeting |
|---|---|---|
| Brain Distribution | Widespread | Region-specific (Cortex/Hippocampus) |
| Side Effect Risk | High (Respiratory/Motor) | Low (Targeted) |
Frequently Asked Questions
What is the role of NMDA receptors in autism?
NMDARs are critical for synaptic signaling. Impaired function of these receptors is associated with social, cognitive, and repetitive behavioral issues found in autism spectrum disorder and other neurological conditions.
How long do the effects of the ASO treatment last?
In mouse studies, a single administration of the ASO remained effective for at least eight weeks without detectable adverse effects, according to the IBS Center for Synaptic Brain Dysfunctions.
Is this treatment currently available for humans?
No. While the results in human cortical organoids are promising, the strategy is currently in the research phase and has not yet moved to human clinical trials.
Follow the latest updates from the IBS Center for Synaptic Brain Dysfunctions to track the progress of this research as it moves toward clinical development.
Have questions about how emerging gene therapies might impact neurodevelopmental research? Sign up for our weekly newsletter to get the latest science news delivered to your inbox.
Keep reading
- American Diabetes Association Members Launch Boycott Over Ejections
- Brain Tumor Patients Demand More Treatment Options
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)